Dextromethadone - Relmada Therapeutics

Drug Profile

Dextromethadone - Relmada Therapeutics

Alternative Names: +-Methadone - Relmada Therapeutics; 6S-Methadone - Relmada Therapeutics; d Methadone - Relmada Therapeutics; REL 1017; S-Methadone - Relmada Therapeutics

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Relmada Therapeutics
  • Class Analgesics; Drug withdrawal therapies; Ketones
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Neuropathic pain
  • Preclinical Major depressive disorder

Most Recent Events

  • 27 Oct 2017 Relmada Therapeutics receives notice of acceptance for patent application number 2 013 323 645 for dextromethadone in Australia
  • 13 Apr 2017 Dextromethadone - Relmada Therapeutics receives Fast Track designation for Major depressive disorder (Adjunctive treatment) [PO] in USA
  • 25 Jan 2017 U.S. Food and Drug Administration (FDA) approves IND application for dextromethadone in Depression (Treatment-resistant)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top